A
Andrew P. Tomaras
Researcher at Pfizer
Publications - 26
Citations - 1345
Andrew P. Tomaras is an academic researcher from Pfizer. The author has contributed to research in topics: Pseudomonas aeruginosa & Acinetobacter baumannii. The author has an hindex of 19, co-authored 26 publications receiving 1179 citations. Previous affiliations of Andrew P. Tomaras include University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
The Influence of Iron on Pseudomonas aeruginosa Physiology A REGULATORY LINK BETWEEN IRON AND QUORUM SENSING
Amanda G. Oglesby,John M. Farrow,Joon Hee Lee,Andrew P. Tomaras,E. P. Greenberg,Everett C. Pesci,Michael L. Vasil +6 more
TL;DR: Iron was capable of activating both antA and antR in a ΔprrF1,2 mutant, indicating the presence of two distinct yet overlapping pathways for iron activation of antA (AntR-dependent and PrrF-dependent).
Journal ArticleDOI
Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa
Seungil Han,Richard P. Zaniewski,Eric S. Marr,Brian M. Lacey,Andrew P. Tomaras,Artem G. Evdokimov,J. Richard Miller,Veerabahu Shanmugasundaram +7 more
TL;DR: A novel conformation that is distinct to the high-molecular-weight class B PBP subfamily is identified, which is identifiable by common features such as a hydrophobic aromatic wall formed by Tyr503, Tyr532, and Phe533 and the structural flexibility of Tyr409 flanked by two glycine residues.
Journal ArticleDOI
Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosa
Andrew P. Tomaras,Jared L. Crandon,Craig J. McPherson,Mary Anne Banevicius,Steven M. Finegan,Rebecca Irvine,Matthew Frank Brown,John P. O'Donnell,David P. Nicolau +8 more
TL;DR: In this article, the authors describe MB-1, a siderophore-conjugated monobactam that demonstrates excellent in vitro activity against Pseudomonas aeruginosa when tested using standard assay conditions.
Journal ArticleDOI
Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections
Justin I. Montgomery,Matthew Frank Brown,Usa Reilly,Loren M. Price,Joseph A. Abramite,Joel T. Arcari,Rose Barham,Ye Che,Jinshan Michael Chen,Seung Won Chung,Elizabeth M. Collantes,Charlene R. Desbonnet,Matthew David Doroski,Jonathan L. Doty,Juntyma J. Engtrakul,Thomas M. Harris,Michael D. Huband,John D. Knafels,Karen L. Leach,Shenping Liu,Anthony Marfat,Laura A. McAllister,Eric B. McElroy,Carol A. Menard,Mark J. Mitton-Fry,Lisa Mullins,Mark C. Noe,John P. O'Donnell,Robert M. Oliver,Joseph Penzien,Mark S. Plummer,Veerabahu Shanmugasundaram,Christy Thoma,Andrew P. Tomaras,Daniel P. Uccello,Alfin D. N. Vaz,Donn G. Wishka +36 more
TL;DR: Members of this series of LpxC inhibitors have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.
Journal ArticleDOI
LpxC Inhibitors as New Antibacterial Agents and Tools for Studying Regulation of Lipid A Biosynthesis in Gram-Negative Pathogens
Andrew P. Tomaras,Craig J. McPherson,Michael Kuhn,Arlene Carifa,Lisa Mullins,David M. George,Charlene R. Desbonnet,Tess M. Eidem,Justin I. Montgomery,Matthew Frank Brown,Usa Reilly,Alita A. Miller,John P. O'Donnell +12 more
TL;DR: The microbiological characterization of LpxC-4, a recently disclosed inhibitor of this bacterial target, is described and it is demonstrated that its spectrum of activity extends to several of the pathogenic species that are most threatening to human health today.